
Thursday, December 21, 2023 9:51:55 AM
Looking for a couple of gentlemanly dollars
As of Dec-21-20239:49:07 AM ET
https://stockcharts.com/h-sc/ui
The News
Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%
BENZINGA
Immunovant Inc (IMVT.NaE) , on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of batoclimab in patients with Graves' disease.
Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones (hyperthyroidism).
The company says the results show that batoclimab meaningfully exceeded 50% response rates.
Consistent with studies of batoclimab in other indications, 680 mg administered subcutaneously (SC) in the initial cohort demonstrated an IgG reduction of up to 87%, with a mean IgG reduction of 81% after 12 weeks of treatment.
The 340 mg IgG reductions were lower. A similar dose response was observed for anti-TSHR autoantibodies, with deeper reductions observed following treatment with 680 mg of SC batoclimab compared to 340 mg of SC batoclimab.
In addition, numerically higher responses were observed following treatment with 680 mg of batoclimab across a range of clinical parameters compared to treatment with 340 mg of batoclimab.
Batoclimab was generally well tolerated, with no new safety signals observed in the initial data set.
Recent IMVT News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/25/2025 08:15:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2025 11:18:30 AM
- Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 • GlobeNewswire Inc. • 04/21/2025 11:00:00 AM
- Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 • GlobeNewswire Inc. • 04/21/2025 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/17/2025 08:08:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/17/2025 08:07:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/11/2025 08:05:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2025 08:55:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2025 08:53:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2025 08:50:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2025 08:48:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2025 08:46:54 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 03/26/2025 08:09:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2025 11:51:41 AM
- Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies • GlobeNewswire Inc. • 03/19/2025 11:45:00 AM
- Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs • GlobeNewswire Inc. • 03/18/2025 08:32:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2025 09:06:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2025 09:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2025 09:04:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/06/2025 11:45:11 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2025 11:37:53 AM
- Immunovant Reports Financial Results for the Quarter Ended December 31, 2024 • GlobeNewswire Inc. • 02/06/2025 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2025 10:24:41 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/24/2025 10:20:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2025 09:22:06 PM
Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement • COEP • Apr 25, 2025 8:33 AM
UAV Corp. Successfully Completes Inflation Test of DART SA-70 Airship, Paving Way for Flight Readiness • UMAV • Apr 24, 2025 8:30 AM
InnerScope Hearing Technologies (OTC: INND) Announces the Grand Opening of OTCHealthMart.com • INND • Apr 24, 2025 8:00 AM
Opus Holdings Unveils Powerhouse Leadership Team to Drive Aggressive Growth and Transform Market Trajectory • CATV • Apr 22, 2025 8:30 AM
Glidelogic Corp. (OTCQB: GDLG) Highlights Independent SOTA Evaluation of ResearchMind Platform • GDLG • Apr 22, 2025 6:54 AM
UAV Corp to Launch Inflation Test of SA-70 Airship This Week-A Gateway to High-Value Government and Defense Contracts • UMAV • Apr 21, 2025 1:30 PM